×
-0.00118623962040325 -0.000128113879003429 -0.00711743772241986 0 0.0272882562277581 0.0320284697508897 0.0344009489916964 0.0320284697508897
Stockreport

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomi...

NOVOCURE LTD ORDINARY SHARES (NVCR)  More Company Research Source: Business Wire
Last novocure ltd ordinary shares earnings: 4/26 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: novocure.com/investor-relations
PDF Health-related quality of life was maintained for a longer period of time in several predefined health scales in EF-14 trial patients treated with a combination of Optune and temozolomide compared to patients treated with temozolomide alone The use of Optune together with temozolomide extended progression free and overall survival in newly diagnosed glioblastoma patients The prespecified analysis concludes that improved progression free and overall survival without a negative influence on health-related quality of life supports the addition of Optune to standard treatment in patients with glioblastoma ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that a detailed quality of life analysis of Novocure’s EF-14 phase 3 pivotal trial of Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma (GBM) has been published in JAMA Oncol [Read more]

IMPACT SNAPSHOT EVENT TIME: NVCR
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
NVCR alerts
from News Quantified